LIWALIWA for Treatment of Alzheimer Patients

Inclusion Criteria:

1. Men and women aged 50-85.
2. Diagnosed with Alzheimer's disease for at least half a year (by the DSM-IV criteria).
3. Scored 16-26 on the MMSE.
4. Received drug therapy for their disease, with each treatment having been administered at an acceptable dosage for at least 5 weeks.
5. Existence of a routine therapist for changes or adverse effects reports.
6. Existence of Alzheimer diagnosis by CT or MRI tests.
7. Answered in the negative to all questions in the pre-TMS treatment safety questionnaire.
8. Gave their oral and written consent to participate in the trial.

Exclusion Criteria:

1. An additional neurological disorder.
2. Severe psychiatric disorder.
3. Uncontrolled hypertension, beyond 170/110.
4. History of epilepsy, seizure, or heat convulsion or History of epilepsy or seizure in first degree relatives.
5. History of head injury or stroke.
6. History of metal implants in the head (except dental fillings)or History of surgery entailing metallic implants or known history of any metallic particles in the eye, implanted cardiac pacemaker, cochlear implants, use of neuro stimulators, or any medical pumps.
7. History of migraines in the last six months.
8. History of drug or alcohol abuse.
9. Inadequate communication with examiner.
10. Participation in another clinical study, either concurrent with this trial or in the 3 months preceding it.
11. Inability to sign a consent form.
12. Leukemia